PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.46 USD | +4.33% |
|
-5.04% | -23.49% |
| May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
| May. 08 | Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.07B 1.15B |
|---|---|---|---|---|---|
| Net income 2024 * | -122M -131M | Net income 2025 * | -138M -149M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 303M | Net cash position 2025 * | 161M 174M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-8.93
x | P/E ratio 2025 * |
-8.17
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | +4.33% | ||
| 1 week | -5.04% | ||
| Current month | -12.73% | ||
| 1 month | -3.81% | ||
| 3 months | -24.73% | ||
| 6 months | +21.93% | ||
| Current year | -23.49% |
1 week
20.14
24.02
1 month
17.5725.50
Current year
17.5733.00
1 year
8.1033.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 21.46 | +4.33% | 66,628 |
| 24-05-09 | 20.57 | -1.34% | 23,166 |
| 24-05-08 | 20.85 | -7.82% | 27,497 |
| 24-05-07 | 22.62 | -0.26% | 45,524 |
| 24-05-06 | 22.68 | +0.35% | 56,526 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-05-13
- Citizens JMP Life Sciences Conference
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
19.93
EUR
Average target price
30.98
EUR
Spread / Average Target
+55.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.49% | 1.15B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- PHVS Stock
